Estamos realizando la búsqueda. Por favor, espere...
1527
37
172
17658
3251
2412
322
Abstract: OBJECTIVES: Prisons are major reservoirs of hepatitis C virus (HCV) in which a therapeutic approach has been particularly difficult so far. Our aim was to create a permanent program of HCV elimination in a prison based on a "test and treat" strategy. METHODS: This open-label clinical trial was conducted in the Spanish prison "El Dueso" between May 2016 and July 2017. Viremic patients were treated with a ledipasvir-sofosbuvir regimen (8-12 weeks) according to the 2015 Spanish Guidelines. A teleconsultation program was established to follow-up patients from the hospital. Non-responders were submitted for a phylogenetic analysis and offered retreatment. An evaluation of new cases of HCV infection was performed every 6 months and upon release in all inmates. RESULTS: 847 (99.5%) inmates accepted to participate. HCV antibodies were present in 110 (13.0%) and 86 (10.2%) had detectable viremia. Most of them were genotype 1 or 3 (82.6%) and had
Fuente: Am J Gastroenterol. 2018 Nov;113(11):1639-1648
Editorial: Springer Nature
Año de publicación: 2018
Nº de páginas: 10
Tipo de publicación: Artículo de Revista
DOI: 10.1038/s41395-018-0157-x
ISSN: 0002-9270,1572-0241
Url de la publicación: https://doi.org/10.1038/s41395-018-0157-x
Consultar en UCrea Leer publicación
ANTONIO CUADRADO LAVIN
SUSANA LLERENA SANTIAGO
COBO, CARMEN
PALLÁS, JOSÉ RAMÓN
MATEO, MIGUEL
JOAQUIN CABEZAS GONZALEZ
JOSE IGNACIO FORTEA ORMAECHEA
ÁLVAREZ, SILVIA
PELLÓN, RAÚL
JUAN CRESPO DEL POZO
SANTIAGO ECHEVARRIA VIERNA
MARIA ROSA AYESA ARRIOLA
Mª ESTHER SETIEN SUERO
MARCOS LOPEZ HOYOS
BENEDICTO CRESPO FACORRO
JESUS AGÜERO BALBIN
CHUECA, NATALIA
GARCIA, FEDERICO
CALLEJA, JOSE LUIS
JAVIER CRESPO GARCIA
Volver